EUVIMEDEUVIMED entdecken
Übersichtsarbeit

New ways of mitigating aldosterone in cardiorenal disease

Felix Götzinger iD, Michael Kunz iD, Lucas Lauder iD, Michael Böhm iD, Felix Mahfoud iD

European Heart Journal - Cardiovascular Pharmacotherapy · 2024

DOI: 10.1093/ehjcvp/pvae049 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Felix Götzinger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III-Cardiology, Angiology and Intensive Care Medicine, Homburg University Hospital, Saarland University, Kirrberger S…. Hauptthemen laut MEDLINE: Aldosterone, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: Deutsche Herzstiftung, AstraZeneca, ReCor Medical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Steroidal mineralocorticoid receptor antagonists (MRAs) bind to the mineralocorticoid receptor and antagonize the effects of aldosterone, which contributes to the development and progression of cardio- and renovascular diseases. Guidelines recommend steroidal MRAs in patients with heart failure with reduced or mildly reduced ejection fraction, as they reduce morbidity and mortality. In heart failure with preserved ejection fraction, MRAs have not convincingly shown to improve prognosis. Steroidal MRAs delay the progression of chronic kidney disease, reduce proteinuria and lower blood pressure in resistant hypertension but can induce hyperkalaemia. Due to their limited selectivity to the mineralocorticoid receptor, steroidal MRAs can cause significant adverse effects, i.e. libido loss, erectile dysfunction, gynaecomastia, and amenorrhoea, leading to low rates of persistance. Against this background, new avenues for developing non-steroidal, selective (ns)MRAs and aldosterone-synthase inhibitors have been taken. Finerenone has been shown to delay the progression of diabetic nephropathy and lower the incidence of heart failure hospitalizations in patients with chronic kidney disease and diabetes compared with placebo. Finerenone has therefore been recommended by the 2023 European Society of Cardiology Guidelines for the management of diabetes in patients with type 2 diabetes and chronic kidney disease. Further randomized controlled trials assessing the safety and effectiveness of finerenone in patients with heart failure are currently ongoing. Esaxerenone provides antihypertensive effects and has been approved for the treatment of hypertension in Japan. Baxdrostat and lorundostat, novel selective aldosterone-synthase inhibitors, are currently under investigation. In phase II trials, baxdrostat and lorundostat were safe and effective in lowering blood pressure in resistant hypertension. In this review, we summarize and critically discuss the evidence for new drugs mitigating aldosterone in heart failure, hypertension, and chronic kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AldosteroneMineralocorticoid Receptor AntagonistsHumansTreatment OutcomeHeart FailureCardio-Renal SyndromeAnimalsRenal Insufficiency, ChronicReceptors, MineralocorticoidNaphthyridines

Stichwörter der Autor:innen

AldosteroneBaxdrostatBlood pressureChronic kidney diseaseFinerenoneHeart failure

Substanzen

AldosteroneMineralocorticoid Receptor AntagonistsfinerenoneReceptors, MineralocorticoidNaphthyridines

Autor:innen und Institutionen

  • Department of Internal Medicine III-Cardiology, Angiology and Intensive Care Medicine, Homburg University Hospital, Saarland University, Kirrberger Str. 100, Homburg 66424, Germany.
  • Department of Cardiology, University Heart Center Basel, University Hospital Basel, Am Petersgraben 4, Basel 4031, Switzerland.

ORCID-Profile: Felix Götzinger, Michael Kunz, Lucas Lauder, Michael Böhm, Felix Mahfoud

Förderung

  • Deutsche Herzstiftung
  • AstraZeneca
  • ReCor Medical
  • Medtronic
  • Deutsche Forschungsgemeinschaft
  • Deutsche Gesellschaft für Kardiologie

Zitieren

APA

Götzinger, F., Kunz, M., Lauder, L., Böhm, M., & Mahfoud, F. (2024). New ways of mitigating aldosterone in cardiorenal disease. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae049

Vancouver

Götzinger F, Kunz M, Lauder L, Böhm M, Mahfoud F. New ways of mitigating aldosterone in cardiorenal disease. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae049

BibTeX
@article{Gtzinger2024,
  author = {Götzinger, Felix and Kunz, Michael and Lauder, Lucas and Böhm, Michael and Mahfoud, Felix},
  title = {New ways of mitigating aldosterone in cardiorenal disease},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  doi = {10.1093/ehjcvp/pvae049}
}
Kostenlos starten →